---
title: "YTHDF2 promotes cutaneous melanoma progression via m6A-dependent HMOX1 regulation of ferroptosis"
id: "pubmed-42848283"
canonical_url: "https://medichelpline.com/clinical-feed/pubmed-42848283"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "PubMed / NCBI"
source_url: "https://pubmed.ncbi.nlm.nih.gov/42848283/"
doi: "10.1007/s12032-026-03427-y"
published_at: "2026-10-08T00:00:00.000Z"
evidence_level: "Journal Article"
license: "CC-BY-NC-4.0 / Informational Use"
---
# YTHDF2 promotes cutaneous melanoma progression via m6A-dependent HMOX1 regulation of ferroptosis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/pubmed-42848283
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** PubMed / NCBI
- **Source URL:** [Original Journal Publication](https://pubmed.ncbi.nlm.nih.gov/42848283/)
- **DOI:** [10.1007/s12032-026-03427-y](https://doi.org/10.1007%2Fs12032-026-03427-y)
- **Published At:** 2026-10-08T00:00:00.000Z
- **Evidence Rating:** Journal Article
## Executive GIST (TL;DR)
- The m6A RNA modification pathway is implicated in cutaneous melanoma; the m6A reader protein **YTHDF2** was investigated for its role in melanoma pathogenesis. - Public database analyses showed **YTHDF2** is upregulated in multiple cancers, including cutaneous melanoma, correlating positively with **PD-L1** expression and negatively with immune and stromal scores. - Knockdown of **YTHDF2** in melanoma cell lines reduced proliferation and increased Annexin V/PI–positive cells; these effects were reversed by a ferroptosis inhibitor, implicating **ferroptosis** in the phenotype. - YTHDF2 depletion increased intracellular Fe2+, malondialdehyde, reactive oxygen species, and lipid peroxidation and reduced glutathione-related effects; these biochemical changes were mitigated by ferroptosis inhibition. - Integrated RNA-seq and RIP-seq data indicated **YTHDF2** binds m6A-modified transcripts of **HMOX1**, promoting destabilization of HMOX1 mRNA and lowering HMOX1 expression. - Metformin treatment suppressed **YTHDF2** expression and promoted ferroptosis in melanoma cells, suggesting potential repurposing avenues. - In vivo experiments supported the regulatory role of **YTHDF2** in ferroptosis and melanoma progression; ethical approval for animal studies was reported. - The study proposes **YTHDF2** as a therapeutic target in melanoma via modulation of m6A-dependent **HMOX1** mRNA stability and ferroptosis regulation; specific experimental details, sample sizes, and quantitative results were not reported in the abstract and require consultation of the full text for complete data.
## Clinical Analysis & Structured Key Points
Clipboard, Search History, and several other advanced features are temporarily unavailable. [ Skip to main page content ](https://pubmed.ncbi.nlm.nih.gov/42848283/#article-details) ![U.S. flag](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png) An official website of the United States government Here's how you know ![Dot gov](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg) **The .gov means it’s official.** Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. ![Https](https://cdn.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg) **The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. [ ![NIH NLM Logo](https://cdn.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg) ](https://www.ncbi.nlm.nih.gov/) [Log in](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42848283%2F) Show account info Close #### Account Logged in as: **username** * [Dashboard](https://www.ncbi.nlm.nih.gov/myncbi/) * [Publications](https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/) * [Account settings](https://www.ncbi.nlm.nih.gov/account/settings/) * [Log out](https://www.ncbi.nlm.nih.gov/account/signout/?back_url=https%3A//pubmed.ncbi.nlm.nih.gov/42848283/) [Access keys](https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys) [NCBI Homepage](https://www.ncbi.nlm.nih.gov) [MyNCBI Homepage](https://pubmed.ncbi.nlm.nih.gov/myncbi/) [Main Content](https://pubmed.ncbi.nlm.nih.gov/42848283/#maincontent) [Main Navigation](https://pubmed.ncbi.nlm.nih.gov/42848283/) [ ![pubmed logo](https://cdn.ncbi.nlm.nih.gov/pubmed/a447896c-976f-490b-b86b-2668b65114a8/core/images/pubmed-logo-blue.svg) ](https://pubmed.ncbi.nlm.nih.gov/) [ ](https://pubmed.ncbi.nlm.nih.gov/42848283/ "Show search bar") Search: [](https://pubmed.ncbi.nlm.nih.gov/42848283/ "Clear search input")Search [Advanced](https://pubmed.ncbi.nlm.nih.gov/advanced/) [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/clipboard/) [ User Guide ](https://pubmed.ncbi.nlm.nih.gov/help/) Save Email Send to * [ Clipboard ](https://pubmed.ncbi.nlm.nih.gov/42848283/) * [My Bibliography](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42848283%2F%23open-bibliography-panel) * [Collections](https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpubmed.ncbi.nlm.nih.gov%2F42848283%2F%23open-collections-panel) * [Citation manager](https://pubmed.ncbi.nlm.nih.gov/42848283/) Display options Display options Format Abstract PubMed PMID ## Save citation to file Format: Summary (text) PubMed PMID Abstract (text) CSV Create file Cancel ## Email citation Email address has not been verified. Go to [ My NCBI account settings ](https://account.ncbi.nlm.nih.gov/settings/) to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email Cancel ### Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42848283/) Add Cancel ### Add to My Bibliography * My Bibliography Unable to load your delegates due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42848283/) Add Cancel ## Your saved search Name of saved search: Search terms: [Test search terms](https://pubmed.ncbi.nlm.nih.gov/42848283/) Would you like email updates of new search results? Saved Search Alert Radio Buttons * Yes * No Email: ([change](https://www.ncbi.nlm.nih.gov/account/settings/)) Frequency: Monthly Weekly Daily Which day? The first Sunday The first Monday The first Tuesday The first Wednesday The first Thursday The first Friday The first Saturday The first day The first weekday Which day? Sunday Monday Tuesday Wednesday Thursday Friday Saturday Report format: Summary Summary (text) Abstract Abstract (text) PubMed Send at most: 1 item 5 items 10 items 20 items 50 items 100 items 200 items Send even when there aren't any new results Optional text in email: Save Cancel ## Create a file for external citation management software Create file Cancel ## Your RSS Feed Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link Copy ### Actions Cite Collections Add to Collections * Create a new collection * Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error [Please try again](https://pubmed.ncbi.nlm.nih.gov/42848283/) Add Cancel Permalink Permalink Copy Display options Display options Format Abstract PubMed PMID ### Experimental Resource Linked Discoveries ### Page navigation * [ Title & authors ](https://pubmed.ncbi.nlm.nih.gov/42848283/#heading) * [ Abstract ](https://pubmed.ncbi.nlm.nih.gov/42848283/#abstract) * [ Conflict of interest statement ](https://pubmed.ncbi.nlm.nih.gov/42848283/#conflict-of-interest) * [ References ](https://pubmed.ncbi.nlm.nih.gov/42848283/#references) * [ MeSH terms ](https://pubmed.ncbi.nlm.nih.gov/42848283/#mesh-terms) * [ Substances ](https://pubmed.ncbi.nlm.nih.gov/42848283/#substances) * [ Grants and funding ](https://pubmed.ncbi.nlm.nih.gov/42848283/#grants) Title & authors Abstract Conflict of interest statement References MeSH terms Substances Grants and funding Med Oncol Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Med+Oncol%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Med+Oncol%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42848283/) . 2026 Oct 8;43(11):316. doi: 10.1007/s12032-026-03427-y. # YTHDF2 drives malignant progression in cutaneous melanoma through m⁶A-dependent HMOX1-mediated ferroptosis [Da Gu](https://pubmed.ncbi.nlm.nih.gov/?term=Gu+D&cauthor_id=42848283)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42848283/#full-view-affiliation-1 "Department of Plastic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42848283/#full-view-affiliation-2 "Department of Plastic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, Shandong, China."), [Yulin Sun](https://pubmed.ncbi.nlm.nih.gov/?term=Sun+Y&cauthor_id=42848283)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42848283/#full-view-affiliation-3 "Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China."), [Jinpeng Sun](https://pubmed.ncbi.nlm.nih.gov/?term=Sun+J&cauthor_id=42848283)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42848283/#full-view-affiliation-3 "Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China."), [Weiting Kang](https://pubmed.ncbi.nlm.nih.gov/?term=Kang+W&cauthor_id=42848283)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42848283/#full-view-affiliation-4 "Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China. kangweiting@sdfmu.edu.cn."), [Huanmin Lou](https://pubmed.ncbi.nlm.nih.gov/?term=Lou+H&cauthor_id=42848283)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42848283/#full-view-affiliation-5 "Department of Plastic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, Shandong, China. 13370582901@189.cn."), [Xiaojing Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+X&cauthor_id=42848283)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42848283/#full-view-affiliation-6 "Department of Plastic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. yfy130377@fy.ahmu.edu.cn.") Affiliations Expand ### Affiliations * 1 Department of Plastic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. * 2 Department of Plastic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, Shandong, China. * 3 Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China. * 4 Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China. kangweiting@sdfmu.edu.cn. * 5 Department of Plastic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, Shandong, China. 13370582901@189.cn. * 6 Department of Plastic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. yfy130377@fy.ahmu.edu.cn. * PMID: **42848283** * DOI: [ 10.1007/s12032-026-03427-y ](https://doi.org/10.1007/s12032-026-03427-y) Item in Clipboard # YTHDF2 drives malignant progression in cutaneous melanoma through m⁶A-dependent HMOX1-mediated ferroptosis Da Gu et al. Med Oncol. 2026. Show details Display options Display options Format Abstract PubMed PMID Med Oncol Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Med+Oncol%22%5Bjour%5D&sort=date&sort_order=desc) * [ Search in NLM Catalog ](https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Med+Oncol%22%5BTitle+Abbreviation%5D) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42848283/) . 2026 Oct 8;43(11):316. doi: 10.1007/s12032-026-03427-y. ### Authors [Da Gu](https://pubmed.ncbi.nlm.nih.gov/?term=Gu+D&cauthor_id=42848283)[ 1 ](https://pubmed.ncbi.nlm.nih.gov/42848283/#short-view-affiliation-1 "Department of Plastic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China.")[ 2 ](https://pubmed.ncbi.nlm.nih.gov/42848283/#short-view-affiliation-2 "Department of Plastic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, Shandong, China."), [Yulin Sun](https://pubmed.ncbi.nlm.nih.gov/?term=Sun+Y&cauthor_id=42848283)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42848283/#short-view-affiliation-3 "Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China."), [Jinpeng Sun](https://pubmed.ncbi.nlm.nih.gov/?term=Sun+J&cauthor_id=42848283)[ 3 ](https://pubmed.ncbi.nlm.nih.gov/42848283/#short-view-affiliation-3 "Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China."), [Weiting Kang](https://pubmed.ncbi.nlm.nih.gov/?term=Kang+W&cauthor_id=42848283)[ 4 ](https://pubmed.ncbi.nlm.nih.gov/42848283/#short-view-affiliation-4 "Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China. kangweiting@sdfmu.edu.cn."), [Huanmin Lou](https://pubmed.ncbi.nlm.nih.gov/?term=Lou+H&cauthor_id=42848283)[ 5 ](https://pubmed.ncbi.nlm.nih.gov/42848283/#short-view-affiliation-5 "Department of Plastic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, Shandong, China. 13370582901@189.cn."), [Xiaojing Li](https://pubmed.ncbi.nlm.nih.gov/?term=Li+X&cauthor_id=42848283)[ 6 ](https://pubmed.ncbi.nlm.nih.gov/42848283/#short-view-affiliation-6 "Department of Plastic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. yfy130377@fy.ahmu.edu.cn.") ### Affiliations * 1 Department of Plastic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. * 2 Department of Plastic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, Shandong, China. * 3 Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China. * 4 Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, 250021, Shandong, China. kangweiting@sdfmu.edu.cn. * 5 Department of Plastic Surgery, Central Hospital Affiliated to Shandong First Medical University, Jinan, 250013, Shandong, China. 13370582901@189.cn. * 6 Department of Plastic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. yfy130377@fy.ahmu.edu.cn. * PMID: **42848283** * DOI: [ 10.1007/s12032-026-03427-y ](https://doi.org/10.1007/s12032-026-03427-y) Item in Clipboard Cite Display options Display options Format Abstract PubMed PMID Linked Discoveries ## Abstract N6-methyladenosine (m6A) modification plays a critical role in eukaryotic mRNA and is significantly associated with cutaneous melanoma. This study investigated the role of the m6A-binding protein YTHDF2 in the pathogenesis of cutaneous melanoma and its potential therapeutic applications. Analyses of public databases indicated that YTHDF2 exhibited elevated expression in various cancers, including cutaneous melanoma, where its levels positively correlated with PD-L1 and negatively correlated with immune and stromal scores. Functionally, the downregulation of YTHDF2 in melanoma cells suppressed proliferation and increased the population of Annexin V/PI--positive cells, an effect that was rescued by the ferroptosis inhibitor, highlighting YTHDF2's involvement in ferroptosis regulation. YTHDF2 knockdown resulted in increased intracellular Fe2+ levels, malondialdehyde, reactive oxygen species, and lipid peroxidation, alongside a reduction in glutathione-effects that were reversed upon ferroptosis inhibition. In vivo studies corroborated the regulatory role of YTHDF2 in ferroptosis. Mechanistically, integrated RNA-seq and RIP-seq analyses demonstrated that YTHDF2 could bind to m6A on HMOX1 transcripts, destabilizing its mRNA and thus regulating HMOX1 expression. Moreover, metformin was shown to inhibit YTHDF2 expression, promoting ferroptosis in melanoma cells. In summary, YTHDF2 modulates ferroptosis in melanoma through the regulation of m6A-dependent HMOX1 mRNA stability, suggesting it as a promising therapeutic target. The capacity of metformin to suppress YTHDF2 indicates its potential utility in hindering melanoma progression. **Keywords:** Cutaneous Melanoma; Ferroptosis; HMOX1; M6A; YTHDF2. © 2026. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement Declarations. Competing interests: The authors declare no competing interests. Ethical approval and consent to participate: The animal studies were reviewed and approved by the Ethics Committee for Animal Studies at Central Hospital Affiliated to Shandong First Medical University. ## References 1. 1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. - [PubMed](https://pubmed.ncbi.nlm.nih.gov/35020204/) 2. 1. Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, et al. Melanoma Lancet. 2018;392(10151):971–84. - [DOI](https://doi.org/10.1016/s0140-6736\(18\)31559-9) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/30238891/) 3. 1. Parra LM, Webster RM. The malignant melanoma market. Nat Rev Drug Discov. 2022;21(7):489–90. - [DOI](https://doi.org/10.1038/d41573-022-00075-5) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/35477778/) 4. 1. Sun H, Meng Y, Yao L, Du S, Li Y, Zhou Q, et al. Ubiquitin-specific protease 22 controls melanoma metastasis and vulnerability to ferroptosis through targeting SIRT1/PTEN/PI3K signaling. MedComm (2020). 2024;5(8):e684. - [DOI](https://doi.org/10.1002/mco2.684) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/39135915/) - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/11318338/) 5. 1. Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, et al. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. Eur J Cancer. 2022;170:236–55. - [DOI](https://doi.org/10.1016/j.ejca.2022.03.008) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/35570085/) Show all 30 references ## MeSH terms * Adenosine* / analogs & derivatives Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Adenosine%2Fanalogs+and+derivatives%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Adenosine) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42848283/) * Adenosine* / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Adenosine%2Fmetabolism%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Adenosine) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42848283/) * Animals Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Animals%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Animals) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42848283/) * Cell Line, Tumor Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cell+Line%2C+Tumor%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cell+Line%2C+Tumor) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42848283/) * Cell Proliferation Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cell+Proliferation%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cell+Proliferation) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42848283/) * Cutaneous Malignant Melanoma Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Cutaneous+Malignant+Melanoma%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Cutaneous+Malignant+Melanoma) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42848283/) * Disease Progression Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Disease+Progression%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Disease+Progression) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42848283/) * Ferroptosis* / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Ferroptosis%2Fgenetics%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Ferroptosis) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42848283/) * Gene Expression Regulation, Neoplastic Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Gene+Expression+Regulation%2C+Neoplastic%22%5BMeSH%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Gene+Expression+Regulation%2C+Neoplastic) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42848283/) * Heme Oxygenase-1* / genetics Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Heme+Oxygenase-1%2Fgenetics%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=Heme+Oxygenase-1) * [ Add to Search ](https://pubmed.ncbi.nlm.nih.gov/42848283/) * Heme Oxygenase-1* / metabolism Actions * [ Search in PubMed ](https://pubmed.ncbi.nlm.nih.gov/?term=%22Heme+Oxygenase-1%2Fmetabolism%22%5BMAJR%5D&sort=date&sort_order=desc) * [ Search in MeSH ](https://www.ncbi.nlm.nih.gov/mesh?term=He
## Related Clinical Research

- [Metformin use and incident breast cancer risk: time-bias–aware meta-analysis and limits for imegli](https://medichelpline.com/clinical-feed/medrxiv-8-metformin-use-and-the-risk-of-incident-breast-cancer-a-systematic-review-and.md)
- [Metabolic reprogramming in the immune microenvironment of Ewing sarcoma — article page summary](https://medichelpline.com/clinical-feed/frontiers-in-immunology-8-metabolic-reprogramming-in-the-immune-microenvironment-of-ewing-sarcoma-from.md)
- [Targeting VISTA for Skin Cancer Immunotherapy: Source Article Not Available](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-targeting-vista-as-a-novel-immunotherapy-for-skin-cancer.md)
- [Mitochondrial Dysfunction in T-Cell Exhaustion and Its Impact on Cancer Immunotherapy](https://medichelpline.com/clinical-feed/pubmed-43059381.md) (DOI: 10.3892/ijo.2026.5959)
- [Metformin alters HMGA1a and RBM3 in breast cancer cells; ESR1 splicing effect varies with density](https://medichelpline.com/clinical-feed/biorxiv-6-metformin-lowers-hmga1a-and-rbm3-protein-in-breast-cancer-cells-and-its-effect.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.